RINVOQ

Medicinal product

(Invented) name

RINVOQ

Active substance (s)

Upadacitinibas

Strength

15 mg

Pharmaceutical form

pailginto atpalaidavimo tabletės

Route (s) of administration

vartoti per burną

Legal status for supply

Receptinis

Narrow therapeutic index (NTI)

No

ATC code (s)

L04AF03, upadacitinib

Marketing authorisation holder

AbbVie Deutschland GmbH & Co. KG , Vokietija

Date of authorisation

2019-12-16

Date of renewal

Documents

Rinvoq paciento kortele.pdf

Rinvoq mokomoji medziaga sveikatos prieziuros specialistams.pdf

Search in EMA Europe

Stage

Registruotas

Controlled?

No

Controlled substance type

Legal basis

8(3)

Procedure number

Marketing authorisation procedure

Centrinė registracija

Qualitative and quantitative composition

Prolonged-release tablet	1 vnt.
Upadacitinibas	15 mg

Packages

PAKID	NPAKID	NPAKID-7	Pack type	Pack size	Type of packaging	Proposed dispensing/classification	Marketing authorisation no.	Supply status	From	To	Package is in foreign language	From	To	Mock-up
102979	89080	1089080	lizdinė plokštelė	N28		Receptinis	EU/1/19/1404/001	Tiekiama	-	-	No	-	-
102980	89081	1089081	buteliukas	N30		Receptinis	EU/1/19/1404/002	Netiekiama	-	-	No	-	-
102981	89082	1089082	lizdinė plokštelė	N84 (3x28)		Receptinis	EU/1/19/1404/003	Netiekiama	-	-	No	-	-
102982	89083	1089083	buteliukas	N90 (3x30)		Receptinis	EU/1/19/1404/004	Netiekiama	-	-	No	-	-
102983	89084	1089084	lizdinė plokštelė	N98 (2x49)		Receptinis	EU/1/19/1404/005	Netiekiama	-	-	No	-	-

Stadijos

Data	Stadija
2019-12-16	Registruotas